Daniel Levangie - Insulet Independent Director
PODD Stock | USD 170.78 1.60 0.95% |
Director
Mr. Daniel J. Levangie is no longer a Executive Vice President President Insulet Drug Delivery of Insulet Corporationrationration. Dec 2016 . From 2011 to February 2015 Mr. Levangie served on our Board of Directors and served as our Lead Independent Director from May 2013 to February 2015. Prior to his employment with the Company Mr. Levangie was the managing partner of ATON Partners a private healthcare investment and management consulting firm. From 2011 to 2013 Mr. Levangie was chief executive officer and director of Dune Medical Devices Inc. a private medical device company. He was also a principal and managing partner at Constitution Medical Investors a private equity firm focused on the healthcare sector a role he held from 2008 to 2013 when Constitution Medical Investors was acquired by Roche Diagnostics Corporationrationration. Mr. Levangie formerly served as president and chief executive officer of Keystone Dental Inc. from 2009 to 2011. From 1992 to 2007 Mr. Levangie held various executive management and leadership roles at Cytyc Corporation most recently as president of Cytyc Surgical until the company was acquired by Hologic Inc. From 1975 to 1992 Mr. Levangie held various sales and marketing management positions at Abbott Laboratories Inc. He currently serves on the boards of directors of Exact Sciences Corporation and Dune Medical Devices Inc. and is a managing member of CereVasc LLC. Mr. Levangie served as a member of the board of directors of ev3 Inc. from 2007 to 2011 and as chairman of the board of directors of ev3 from 2008 to 2011 since 2015.
Age | 64 |
Tenure | 9 years |
Address | 100 Nagog Park, Acton, MA, United States, 01720 |
Phone | 978 600 7000 |
Web | https://www.insulet.com |
Insulet Management Efficiency
The company has return on total asset (ROA) of 0.0609 % which means that it generated a profit of $0.0609 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3413 %, meaning that it created $0.3413 on every $100 dollars invested by stockholders. Insulet's management efficiency ratios could be used to measure how well Insulet manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.11. The current year's Return On Assets is expected to grow to 0.08. At present, Insulet's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 1.1 B, whereas Other Assets are forecasted to decline to 0.95.Similar Executives
Showing other executives | DIRECTOR Age | ||
Eric Foss | Cigna Corp | 62 | |
Aaref Hilaly | Guardant Health | 46 | |
Sanders Williams | Laboratory | 69 | |
Garheng Kong | Laboratory | 45 | |
Jane Henney | Cigna Corp | 69 | |
Eric Wiseman | Cigna Corp | 65 | |
Enrique Sosa | Mednax Inc | 79 | |
James Rogers | Cigna Corp | 69 | |
Samir Kaul | Guardant Health | 44 | |
Dipchand Nishar | Guardant Health | N/A | |
John Partridge | Cigna Corp | 71 | |
Roman Martinez | Cigna Corp | 71 | |
Ian Clark | Guardant Health | 57 | |
Manuel Kadre | Mednax Inc | 54 | |
Bahija Jallal | Guardant Health | 56 | |
Pascal Goldschmidt | Mednax Inc | 65 | |
Waldemar Carlo | Mednax Inc | 67 | |
Peter Neupert | Laboratory | 65 | |
Michael Fernandez | Mednax Inc | 66 | |
Michelle Gass | Cigna Corp | 47 | |
Jeffrey Davis | Laboratory | 57 |
Management Performance
Return On Equity | 0.34 | ||||
Return On Asset | 0.0609 |
Insulet Leadership Team
Elected by the shareholders, the Insulet's board of directors comprises two types of representatives: Insulet inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Insulet. The board's role is to monitor Insulet's management team and ensure that shareholders' interests are well served. Insulet's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Insulet's outside directors are responsible for providing unbiased perspectives on the board's policies.
Eric Benjamin, Senior Vice President R&D, New Product Development and Commercialization | ||
Sally Crawford, Lead Independent Director | ||
John Fallon, Independent Director | ||
Mark Field, Senior CTO | ||
Laetitia Cousin, Quality Affairs | ||
Deborah Gordon, Vice President Investor Relations and Corporate Communications | ||
Daniel Levangie, Independent Director | ||
James Mullen, Independent Director | ||
John Kapples, Senior Vice President General Counsel, Secretary | ||
Patrick Sullivan, CEO and President and Director | ||
Wayde McMillan, CFO, Executive Vice President | ||
Charles Liamos, Director of Advanced Technology and Director | ||
Michael Levitz, CFO | ||
Bradley Thomas, Executive VP of HR and Organizational Devel. | ||
Charles Alpuche, Senior Vice President Global Manufacturing and Operations | ||
David Lemoine, Independent Director | ||
James Hollingshead, CEO President | ||
Jessica Hopfield, Director | ||
David Colleran, Vice President General Counsel | ||
Brittany Bradrick, Vice President - Strategy and Corporate Development | ||
Bret Christensen, Chief Commercial Officer | ||
Deborah CPA, Vice Relations | ||
Timothy Scannell, Director | ||
Michael Minogue, Independent Director | ||
Steven Sobieski, Independent Director | ||
Aiman AbdelMalek, Senior Vice President Advanced Technology and Engineering | ||
Corinne Nevinny, Independent Director | ||
Regina Sommer, Independent Director | ||
Mark Licari, Vice President - Global Manufacturing and Operations | ||
Prem Singh, Senior Operations | ||
Angela Wiczek, Senior Communications | ||
Lauren Budden, Chief VP | ||
Michael Spears, Senior Vice President Quality, Regulatory, and Clinical Affairs | ||
Joseph Zakrzewski, Independent Director | ||
Shacey Petrovic, Chief Commercial Officer | ||
Trang Ly, Vice President and Medical Director |
Insulet Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Insulet a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.34 | ||||
Return On Asset | 0.0609 | ||||
Profit Margin | 0.12 % | ||||
Operating Margin | 0.26 % | ||||
Current Valuation | 12.54 B | ||||
Shares Outstanding | 69.93 M | ||||
Shares Owned By Insiders | 0.46 % | ||||
Shares Owned By Institutions | 99.54 % | ||||
Number Of Shares Shorted | 2.8 M | ||||
Price To Book | 16.15 X |
Insulet Investors Sentiment
The influence of Insulet's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Insulet. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Insulet's public news can be used to forecast risks associated with an investment in Insulet. The trend in average sentiment can be used to explain how an investor holding Insulet can time the market purely based on public headlines and social activities around Insulet. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Insulet's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Insulet's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Insulet's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Insulet.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Insulet in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Insulet's short interest history, or implied volatility extrapolated from Insulet options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Insulet using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Insulet. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Insulet Stock refer to our How to Trade Insulet Stock guide.Note that the Insulet information on this page should be used as a complementary analysis to other Insulet's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Insulet Stock analysis
When running Insulet's price analysis, check to measure Insulet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insulet is operating at the current time. Most of Insulet's value examination focuses on studying past and present price action to predict the probability of Insulet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insulet's price. Additionally, you may evaluate how the addition of Insulet to your portfolios can decrease your overall portfolio volatility.
CEOs Directory Screen CEOs from public companies around the world | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is Insulet's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insulet. If investors know Insulet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insulet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.043 | Earnings Share 2.94 | Revenue Per Share 24.331 | Quarterly Revenue Growth 0.379 | Return On Assets 0.0609 |
The market value of Insulet is measured differently than its book value, which is the value of Insulet that is recorded on the company's balance sheet. Investors also form their own opinion of Insulet's value that differs from its market value or its book value, called intrinsic value, which is Insulet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insulet's market value can be influenced by many factors that don't directly affect Insulet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insulet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insulet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insulet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.